share_log

Novavax | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-SK bioscience Co., Ltd.(4.6%),SK chemicals Co., Ltd.(4.6%), etc.

Novavax | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-SK bioscience Co., Ltd.(4.6%),SK chemicals Co., Ltd.(4.6%), etc.

諾瓦瓦克斯醫藥 | SC 13G/A:超過5%持股股東披露文件(修正)-SK bioscience Co., Ltd.(4.6%),SK chemicals Co., Ltd.(4.6%)等
美股sec公告 ·  06/20 14:38
Moomoo AI 已提取核心訊息
Novavax, Inc., a biotechnology company specializing in vaccine development, has experienced a significant change in its shareholder structure. SK bioscience Co., Ltd., SK chemicals Co., Ltd., and SK discovery Co., Ltd., all based in the Republic of Korea, have filed an exit filing with the United States Securities and Exchange Commission, indicating that they are no longer beneficial owners of more than five percent of Novavax's outstanding common stock. This amendment, filed on June 20, 2024, follows a securities subscription agreement dated August 8, 2023, and is based on the number of shares outstanding as of April 30, 2024, as reported in Novavax's Form 10-Q. Each of the reporting companies had shared voting and dispositive power over 6,500,000 shares, representing 4.6% of the class. The exit filing signifies that the companies have ceased to be the beneficial owner of more than five percent of Novavax's shares, a move that could potentially impact the company's stock performance and investor relations.
Novavax, Inc., a biotechnology company specializing in vaccine development, has experienced a significant change in its shareholder structure. SK bioscience Co., Ltd., SK chemicals Co., Ltd., and SK discovery Co., Ltd., all based in the Republic of Korea, have filed an exit filing with the United States Securities and Exchange Commission, indicating that they are no longer beneficial owners of more than five percent of Novavax's outstanding common stock. This amendment, filed on June 20, 2024, follows a securities subscription agreement dated August 8, 2023, and is based on the number of shares outstanding as of April 30, 2024, as reported in Novavax's Form 10-Q. Each of the reporting companies had shared voting and dispositive power over 6,500,000 shares, representing 4.6% of the class. The exit filing signifies that the companies have ceased to be the beneficial owner of more than five percent of Novavax's shares, a move that could potentially impact the company's stock performance and investor relations.
生物技術公司Novavax, Inc.在疫苗開發方面有所專長。SK bioscience Co., Ltd.、SK chemicals Co., Ltd.和SK discovery Co., Ltd.都是韓國的公司,在擁有Novavax的普通股中不再是超過5%的受益所有者。這項修正案於2024年6月20日提交,並根據Novavax的10-Q表格中報告的截至2024年4月30日的流通股份數量進行。每個報告公司均在該類別中共享投票權和處分權,持有650萬股,佔該類別的4.6%。退出備案表明這些公司已停止擁有五分之一以上Novavax的股份,這可能會對該公司的股票表現和投資者關係產生潛在影響。
生物技術公司Novavax, Inc.在疫苗開發方面有所專長。SK bioscience Co., Ltd.、SK chemicals Co., Ltd.和SK discovery Co., Ltd.都是韓國的公司,在擁有Novavax的普通股中不再是超過5%的受益所有者。這項修正案於2024年6月20日提交,並根據Novavax的10-Q表格中報告的截至2024年4月30日的流通股份數量進行。每個報告公司均在該類別中共享投票權和處分權,持有650萬股,佔該類別的4.6%。退出備案表明這些公司已停止擁有五分之一以上Novavax的股份,這可能會對該公司的股票表現和投資者關係產生潛在影響。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息